User profiles for "author:M. Rizk"
Mina M. RizkIcahn School of Medicine at Mount Sinai; Columbia University; Minia University Verified email at mountsinai.org Cited by 536 |
Quality indicators for colonoscopy
DK Rex, PS Schoenfeld, J Cohen, IM Pike… - Official journal of the …, 2015 - journals.lww.com
Colonoscopy is widely used for the diagnosis and treatment of colon disorders. Properly
performed, colonoscopy is generally safe, accurate, and well-tolerated. Visualization of the …
performed, colonoscopy is generally safe, accurate, and well-tolerated. Visualization of the …
Quality indicators for ERCP
DG Adler, JG Lieb, J Cohen, IM Pike… - Official journal of the …, 2015 - journals.lww.com
92 vital signs during sedation, then the performance target was listed as> 98%. It is
important to emphasize that the performance targets listed do not necessarily reflect the …
important to emphasize that the performance targets listed do not necessarily reflect the …
Nitric oxide and wound healing
M Rizk, MB Witte, A Barbul - World journal of surgery, 2004 - Springer
Nitric oxide is a short-lived free radical that acts at the molecular, cellular, and physiologic
level. Since its discovery almost 20 years ago it has proven itself as an important element in …
level. Since its discovery almost 20 years ago it has proven itself as an important element in …
CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein
…, Z Ao, Y Yoon, MX Wu, M Rizk… - Proceedings of the …, 1997 - National Acad Sciences
Members of the tumor necrosis factor receptor (TNFR) superfamily are important for cell
growth and survival. In addition to providing costimulatory signals for cell proliferation …
growth and survival. In addition to providing costimulatory signals for cell proliferation …
[PDF][PDF] Ensemble modeling of metabolic networks
LM Tran, ML Rizk, JC Liao - Biophysical journal, 2008 - cell.com
Complete modeling of metabolic networks is desirable, but it is difficult to accomplish
because of the lack of kinetics. As a step toward this goal, we have developed an approach …
because of the lack of kinetics. As a step toward this goal, we have developed an approach …
A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital …
I Titov, RG Wunderink, A Roquilly… - Clinical Infectious …, 2021 - academic.oup.com
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad
antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We …
antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We …
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
JJ Eron, JK Rockstroh, J Reynes… - The Lancet infectious …, 2011 - thelancet.com
Background Twice-daily raltegravir with once-daily tenofovir-emtricitabine is an effective
initial antiretroviral regimen for patients with HIV-1. On the basis of pharmacokinetic data …
initial antiretroviral regimen for patients with HIV-1. On the basis of pharmacokinetic data …
Quality indicators common to all GI endoscopic procedures
MK Rizk, MS Sawhney, J Cohen, IM Pike… - Official journal of the …, 2015 - journals.lww.com
Quality of care is the degree to which health services for individuals and populations
increase the likelihood of desired health outcomes and are consistent with current …
increase the likelihood of desired health outcomes and are consistent with current …
Quality indicators for EGD
WG Park, NJ Shaheen, J Cohen, IM Pike… - Official journal of the …, 2015 - journals.lww.com
61 literature when available. When data were unavailable to support establishing a
performance target level,“N/A”(not available) was listed. However, when expert consensus …
performance target level,“N/A”(not available) was listed. However, when expert consensus …
Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection
C Lucasti, L Vasile, D Sandesc… - Antimicrobial agents …, 2016 - Am Soc Microbiol
ABSTRACT Relebactam (REL [MK-7655]) is a novel class A/C β-lactamase inhibitor
intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL …
intended for use with imipenem for the treatment of Gram-negative bacterial infections. REL …